Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium chloride 0.9% is an isotonic solution that provides sodium and chloride ions, essential for maintenance of osmotic pressure and fluid balance. It acts as a volume expander and vehicle for drug administration.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Restoration of water and electrolyte balance in dehydration,Fluid resuscitation in hypovolemia,Diluent for intravenous drug administration,Maintenance of intravenous lines,Treatment of hyponatremia
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous infusion; 0.9% sodium chloride is administered at a rate and volume determined by the patient's fluid and electrolyte needs, typically 500-1000 m L per hour for resuscitation or 100-200 m L per hour for maintenance.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
The terminal elimination half-life of sodium and chloride ions is approximately 8-12 hours in individuals with normal renal function, reflecting the time required to excrete a load and reestablish homeostasis. In renal impairment, half-life is prolonged proportionally to the decrease in glomerular filtration rate.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Sodium chloride is not metabolized; it is excreted unchanged primarily by the kidneys.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Primarily renal excretion; >90% of administered sodium and chloride ions are eliminated unchanged in urine via glomerular filtration and tubular reabsorption. Less than 10% is lost through sweat, feces, and insensible losses.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Sodium and chloride ions are not bound to plasma proteins; protein binding is negligible (<1%).
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
The apparent volume of distribution for sodium is approximately 0.2-0.5 L/kg, reflecting distribution primarily in extracellular fluid (ECF). Chloride distributes similarly. This Vd indicates that sodium chloride does not extensively penetrate cells and remains largely in the intravascular and interstitial spaces.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Oral: approximately 100% (sodium chloride is completely absorbed from the gastrointestinal tract). Intravenous: 100% (direct administration into bloodstream).
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
No dose adjustment required for renal impairment; use caution in severe renal impairment due to risk of volume overload and hypernatremia.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No dose adjustment required for hepatic impairment; monitor for fluid overload.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Intravenous infusion; maintenance dose 100-150 m L/kg/day for children up to 10 kg, 50-100 m L/kg/day for 10-20 kg, and 30-50 m L/kg/day for >20 kg; adjust as per clinical need.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Use caution due to increased risk of volume overload; start at low infusion rates and titrate based on clinical response, renal function, and cardiovascular status.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
None.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Use with caution in patients with congestive heart failure, renal impairment, or conditions predisposing to fluid overload,Monitor serum electrolytes and fluid balance regularly,Avoid in patients with hypernatremia or fluid overload,Risk of dilutional hyponatremia with excessive use
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypernatremia,Fluid overload states (e.g., pulmonary edema),Hypersensitivity to sodium chloride,Severe renal impairment with oliguria or anuria
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No known food interactions. Maintain normal dietary sodium intake unless restricted by medical condition.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Sodium chloride 0.9% is a crystalloid solution that maintains extracellular fluid volume and osmolality. It is not teratogenic; no fetal malformations have been reported. During pregnancy, excessive sodium administration may lead to fluid overload and edema in the mother, which can compromise placental perfusion. There is no known direct fetal risk from therapeutic use.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Sodium chloride is a normal constituent of breast milk. Intravenous infusion of 0.9% saline does not significantly alter milk sodium concentration. M/P ratio is not applicable as sodium is endogenous. Use during breastfeeding is considered safe.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
No specific dose adjustment required. However, pregnant women may be more susceptible to fluid overload; use the minimum effective volume and rate. Monitor for hypernatremia or hyponatremia, especially with prolonged infusion.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
0.9% sodium chloride is isotonic and is the preferred crystalloid for resuscitation in hemorrhagic shock, diabetic ketoacidosis, and hypercalcemia. Monitor for hyperchloremic metabolic acidosis with large volumes. Use with caution in patients with heart failure, renal impairment, or hyponatremia.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
This solution is used to replace fluids and electrolytes in your body.,Tell your healthcare provider if you have heart failure, kidney disease, or swelling.,Report any signs of fluid overload such as shortness of breath, swelling in your ankles or legs.,Do not use if the container is damaged or the solution is cloudy.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER is a Electrolyte that works by Sodium chloride 0.9% is an isotonic solution that provides sodium and chloride ions, essential for maintenance of osmotic pressure and fluid balance. It acts as a volume expander and vehicle for drug administration.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER is: Intravenous infusion; 0.9% sodium chloride is administered at a rate and volume determined by the patient's fluid and electrolyte needs, typically 500-1000 m L per hour for resuscitation or 100-200 m L per hour for maintenance.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER is classified as Category A/B. Sodium chloride 0.9% is a crystalloid solution that maintains extracellular fluid volume and osmolality. It is not teratogenic; no fetal malformations have been reported. During pr. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.